Report Detail

Request for Sample of this report

Pharma & Healthcare Global Multiple Sclerosis (MS) Drugs Market Insights, Forecast to 2025

  • RnM3252186
    • |
  • 01 July, 2020
    • |
  • Global
    • |
  • 151 Pages
    • |
  • QYResearch
    • |
  • Pharma & Healthcare

Multiple Sclerosis (MS) Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Multiple Sclerosis (MS) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Multiple Sclerosis (MS) Drugs market is segmented into
Copaxone (Glatiramer Acetate, Copolymer 1)
Novantrone (Mitoxantrone)
Gilenya (Fingolimod, Fty720)
Aubagio (Teriflunomide)
Tecfidera (Dimethyl Fumarate)
Firategrast (Sb683699, T-0047)
Siponimod (Baf312)
Others

Segment by Application, the Multiple Sclerosis (MS) Drugs market is segmented into
RRMS
SPMS
PPMS
PRMS

Regional and Country-level Analysis
The Multiple Sclerosis (MS) Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Multiple Sclerosis (MS) Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Multiple Sclerosis (MS) Drugs Market Share Analysis
Multiple Sclerosis (MS) Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Multiple Sclerosis (MS) Drugs business, the date to enter into the Multiple Sclerosis (MS) Drugs market, Multiple Sclerosis (MS) Drugs product introduction, recent developments, etc.

The major vendors covered:
Bayer AG
Bayhill Therapeutics
Biogen Idec
Cinnagen
Daiichi Sankyo
Eli Lilly
Fast Forward Llc
Antisense Therapeutics
Apitope
Five Prime Therapeutics
Genmab
Artielle Immunotherapeutics
Genzyme
Glaxosmithkline
Gw Pharmaceuticals
Innate Immunotherapeutics


1 Study Coverage

  • 1.1 Multiple Sclerosis (MS) Drugs Product Introduction
  • 1.2 Market Segments
  • 1.3 Key Multiple Sclerosis (MS) Drugs Manufacturers Covered: Ranking by Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Multiple Sclerosis (MS) Drugs Market Size Growth Rate by Type
    • 1.4.2 Copaxone (Glatiramer Acetate, Copolymer 1)
    • 1.4.3 Novantrone (Mitoxantrone)
    • 1.4.4 Gilenya (Fingolimod, Fty720)
    • 1.4.5 Aubagio (Teriflunomide)
    • 1.4.6 Tecfidera (Dimethyl Fumarate)
    • 1.4.7 Firategrast (Sb683699, T-0047)
    • 1.4.8 Siponimod (Baf312)
    • 1.4.9 Others
  • 1.5 Market by Application
    • 1.5.1 Global Multiple Sclerosis (MS) Drugs Market Size Growth Rate by Application
    • 1.5.2 RRMS
    • 1.5.3 SPMS
    • 1.5.4 PPMS
    • 1.5.5 PRMS
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Executive Summary

  • 2.1 Global Multiple Sclerosis (MS) Drugs Market Size, Estimates and Forecasts
    • 2.1.1 Global Multiple Sclerosis (MS) Drugs Revenue 2015-2026
    • 2.1.2 Global Multiple Sclerosis (MS) Drugs Sales 2015-2026
  • 2.2 Global Multiple Sclerosis (MS) Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
    • 2.2.1 Global Multiple Sclerosis (MS) Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
    • 2.2.2 Global Multiple Sclerosis (MS) Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Multiple Sclerosis (MS) Drugs Competitor Landscape by Players

  • 3.1 Multiple Sclerosis (MS) Drugs Sales by Manufacturers
    • 3.1.1 Multiple Sclerosis (MS) Drugs Sales by Manufacturers (2015-2020)
    • 3.1.2 Multiple Sclerosis (MS) Drugs Sales Market Share by Manufacturers (2015-2020)
  • 3.2 Multiple Sclerosis (MS) Drugs Revenue by Manufacturers
    • 3.2.1 Multiple Sclerosis (MS) Drugs Revenue by Manufacturers (2015-2020)
    • 3.2.2 Multiple Sclerosis (MS) Drugs Revenue Share by Manufacturers (2015-2020)
    • 3.2.3 Global Multiple Sclerosis (MS) Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
    • 3.2.4 Global Top 10 and Top 5 Companies by Multiple Sclerosis (MS) Drugs Revenue in 2019
    • 3.2.5 Global Multiple Sclerosis (MS) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Multiple Sclerosis (MS) Drugs Price by Manufacturers
  • 3.4 Multiple Sclerosis (MS) Drugs Manufacturing Base Distribution, Product Types
    • 3.4.1 Multiple Sclerosis (MS) Drugs Manufacturers Manufacturing Base Distribution, Headquarters
    • 3.4.2 Manufacturers Multiple Sclerosis (MS) Drugs Product Type
    • 3.4.3 Date of International Manufacturers Enter into Multiple Sclerosis (MS) Drugs Market
  • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

  • 4.1 Global Multiple Sclerosis (MS) Drugs Market Size by Type (2015-2020)
    • 4.1.1 Global Multiple Sclerosis (MS) Drugs Sales by Type (2015-2020)
    • 4.1.2 Global Multiple Sclerosis (MS) Drugs Revenue by Type (2015-2020)
    • 4.1.3 Multiple Sclerosis (MS) Drugs Average Selling Price (ASP) by Type (2015-2026)
  • 4.2 Global Multiple Sclerosis (MS) Drugs Market Size Forecast by Type (2021-2026)
    • 4.2.1 Global Multiple Sclerosis (MS) Drugs Sales Forecast by Type (2021-2026)
    • 4.2.2 Global Multiple Sclerosis (MS) Drugs Revenue Forecast by Type (2021-2026)
    • 4.2.3 Multiple Sclerosis (MS) Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
  • 4.3 Global Multiple Sclerosis (MS) Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)

  • 5.1 Global Multiple Sclerosis (MS) Drugs Market Size by Application (2015-2020)
    • 5.1.1 Global Multiple Sclerosis (MS) Drugs Sales by Application (2015-2020)
    • 5.1.2 Global Multiple Sclerosis (MS) Drugs Revenue by Application (2015-2020)
    • 5.1.3 Multiple Sclerosis (MS) Drugs Price by Application (2015-2020)
  • 5.2 Multiple Sclerosis (MS) Drugs Market Size Forecast by Application (2021-2026)
    • 5.2.1 Global Multiple Sclerosis (MS) Drugs Sales Forecast by Application (2021-2026)
    • 5.2.2 Global Multiple Sclerosis (MS) Drugs Revenue Forecast by Application (2021-2026)
    • 5.2.3 Global Multiple Sclerosis (MS) Drugs Price Forecast by Application (2021-2026)

6 North America

  • 6.1 North America Multiple Sclerosis (MS) Drugs by Country
    • 6.1.1 North America Multiple Sclerosis (MS) Drugs Sales by Country
    • 6.1.2 North America Multiple Sclerosis (MS) Drugs Revenue by Country
    • 6.1.3 U.S.
    • 6.1.4 Canada
  • 6.2 North America Multiple Sclerosis (MS) Drugs Market Facts & Figures by Type
  • 6.3 North America Multiple Sclerosis (MS) Drugs Market Facts & Figures by Application

7 Europe

  • 7.1 Europe Multiple Sclerosis (MS) Drugs by Country
    • 7.1.1 Europe Multiple Sclerosis (MS) Drugs Sales by Country
    • 7.1.2 Europe Multiple Sclerosis (MS) Drugs Revenue by Country
    • 7.1.3 Germany
    • 7.1.4 France
    • 7.1.5 U.K.
    • 7.1.6 Italy
    • 7.1.7 Russia
  • 7.2 Europe Multiple Sclerosis (MS) Drugs Market Facts & Figures by Type
  • 7.3 Europe Multiple Sclerosis (MS) Drugs Market Facts & Figures by Application

8 Asia Pacific

  • 8.1 Asia Pacific Multiple Sclerosis (MS) Drugs by Region
    • 8.1.1 Asia Pacific Multiple Sclerosis (MS) Drugs Sales by Region
    • 8.1.2 Asia Pacific Multiple Sclerosis (MS) Drugs Revenue by Region
    • 8.1.3 China
    • 8.1.4 Japan
    • 8.1.5 South Korea
    • 8.1.6 India
    • 8.1.7 Australia
    • 8.1.8 Taiwan
    • 8.1.9 Indonesia
    • 8.1.10 Thailand
    • 8.1.11 Malaysia
    • 8.1.12 Philippines
    • 8.1.13 Vietnam
  • 8.2 Asia Pacific Multiple Sclerosis (MS) Drugs Market Facts & Figures by Type
  • 8.3 Asia Pacific Multiple Sclerosis (MS) Drugs Market Facts & Figures by Application

9 Latin America

  • 9.1 Latin America Multiple Sclerosis (MS) Drugs by Country
    • 9.1.1 Latin America Multiple Sclerosis (MS) Drugs Sales by Country
    • 9.1.2 Latin America Multiple Sclerosis (MS) Drugs Revenue by Country
    • 9.1.3 Mexico
    • 9.1.4 Brazil
    • 9.1.5 Argentina
  • 9.2 Central & South America Multiple Sclerosis (MS) Drugs Market Facts & Figures by Type
  • 9.3 Central & South America Multiple Sclerosis (MS) Drugs Market Facts & Figures by Application

10 Middle East and Africa

  • 10.1 Middle East and Africa Multiple Sclerosis (MS) Drugs by Country
    • 10.1.1 Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Country
    • 10.1.2 Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue by Country
    • 10.1.3 Turkey
    • 10.1.4 Saudi Arabia
    • 10.1.5 U.A.E
  • 10.2 Middle East and Africa Multiple Sclerosis (MS) Drugs Market Facts & Figures by Type
  • 10.3 Middle East and Africa Multiple Sclerosis (MS) Drugs Market Facts & Figures by Application

11 Company Profiles

  • 11.1 Bayer AG
    • 11.1.1 Bayer AG Corporation Information
    • 11.1.2 Bayer AG Description and Business Overview
    • 11.1.3 Bayer AG Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 Bayer AG Multiple Sclerosis (MS) Drugs Products Offered
    • 11.1.5 Bayer AG Related Developments
  • 11.2 Bayhill Therapeutics
    • 11.2.1 Bayhill Therapeutics Corporation Information
    • 11.2.2 Bayhill Therapeutics Description and Business Overview
    • 11.2.3 Bayhill Therapeutics Sales, Revenue and Gross Margin (2015-2020)
    • 11.2.4 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Products Offered
    • 11.2.5 Bayhill Therapeutics Related Developments
  • 11.3 Biogen Idec
    • 11.3.1 Biogen Idec Corporation Information
    • 11.3.2 Biogen Idec Description and Business Overview
    • 11.3.3 Biogen Idec Sales, Revenue and Gross Margin (2015-2020)
    • 11.3.4 Biogen Idec Multiple Sclerosis (MS) Drugs Products Offered
    • 11.3.5 Biogen Idec Related Developments
  • 11.4 Cinnagen
    • 11.4.1 Cinnagen Corporation Information
    • 11.4.2 Cinnagen Description and Business Overview
    • 11.4.3 Cinnagen Sales, Revenue and Gross Margin (2015-2020)
    • 11.4.4 Cinnagen Multiple Sclerosis (MS) Drugs Products Offered
    • 11.4.5 Cinnagen Related Developments
  • 11.5 Daiichi Sankyo
    • 11.5.1 Daiichi Sankyo Corporation Information
    • 11.5.2 Daiichi Sankyo Description and Business Overview
    • 11.5.3 Daiichi Sankyo Sales, Revenue and Gross Margin (2015-2020)
    • 11.5.4 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Products Offered
    • 11.5.5 Daiichi Sankyo Related Developments
  • 11.6 Eli Lilly
    • 11.6.1 Eli Lilly Corporation Information
    • 11.6.2 Eli Lilly Description and Business Overview
    • 11.6.3 Eli Lilly Sales, Revenue and Gross Margin (2015-2020)
    • 11.6.4 Eli Lilly Multiple Sclerosis (MS) Drugs Products Offered
    • 11.6.5 Eli Lilly Related Developments
  • 11.7 Fast Forward Llc
    • 11.7.1 Fast Forward Llc Corporation Information
    • 11.7.2 Fast Forward Llc Description and Business Overview
    • 11.7.3 Fast Forward Llc Sales, Revenue and Gross Margin (2015-2020)
    • 11.7.4 Fast Forward Llc Multiple Sclerosis (MS) Drugs Products Offered
    • 11.7.5 Fast Forward Llc Related Developments
  • 11.8 Antisense Therapeutics
    • 11.8.1 Antisense Therapeutics Corporation Information
    • 11.8.2 Antisense Therapeutics Description and Business Overview
    • 11.8.3 Antisense Therapeutics Sales, Revenue and Gross Margin (2015-2020)
    • 11.8.4 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Products Offered
    • 11.8.5 Antisense Therapeutics Related Developments
  • 11.9 Apitope
    • 11.9.1 Apitope Corporation Information
    • 11.9.2 Apitope Description and Business Overview
    • 11.9.3 Apitope Sales, Revenue and Gross Margin (2015-2020)
    • 11.9.4 Apitope Multiple Sclerosis (MS) Drugs Products Offered
    • 11.9.5 Apitope Related Developments
  • 11.10 Five Prime Therapeutics
    • 11.10.1 Five Prime Therapeutics Corporation Information
    • 11.10.2 Five Prime Therapeutics Description and Business Overview
    • 11.10.3 Five Prime Therapeutics Sales, Revenue and Gross Margin (2015-2020)
    • 11.10.4 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Products Offered
    • 11.10.5 Five Prime Therapeutics Related Developments
  • 11.1 Bayer AG
    • 11.1.1 Bayer AG Corporation Information
    • 11.1.2 Bayer AG Description and Business Overview
    • 11.1.3 Bayer AG Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 Bayer AG Multiple Sclerosis (MS) Drugs Products Offered
    • 11.1.5 Bayer AG Related Developments
  • 11.12 Artielle Immunotherapeutics
    • 11.12.1 Artielle Immunotherapeutics Corporation Information
    • 11.12.2 Artielle Immunotherapeutics Description and Business Overview
    • 11.12.3 Artielle Immunotherapeutics Sales, Revenue and Gross Margin (2015-2020)
    • 11.12.4 Artielle Immunotherapeutics Products Offered
    • 11.12.5 Artielle Immunotherapeutics Related Developments
  • 11.13 Genzyme
    • 11.13.1 Genzyme Corporation Information
    • 11.13.2 Genzyme Description and Business Overview
    • 11.13.3 Genzyme Sales, Revenue and Gross Margin (2015-2020)
    • 11.13.4 Genzyme Products Offered
    • 11.13.5 Genzyme Related Developments
  • 11.14 Glaxosmithkline
    • 11.14.1 Glaxosmithkline Corporation Information
    • 11.14.2 Glaxosmithkline Description and Business Overview
    • 11.14.3 Glaxosmithkline Sales, Revenue and Gross Margin (2015-2020)
    • 11.14.4 Glaxosmithkline Products Offered
    • 11.14.5 Glaxosmithkline Related Developments
  • 11.15 Gw Pharmaceuticals
    • 11.15.1 Gw Pharmaceuticals Corporation Information
    • 11.15.2 Gw Pharmaceuticals Description and Business Overview
    • 11.15.3 Gw Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
    • 11.15.4 Gw Pharmaceuticals Products Offered
    • 11.15.5 Gw Pharmaceuticals Related Developments
  • 11.16 Innate Immunotherapeutics
    • 11.16.1 Innate Immunotherapeutics Corporation Information
    • 11.16.2 Innate Immunotherapeutics Description and Business Overview
    • 11.16.3 Innate Immunotherapeutics Sales, Revenue and Gross Margin (2015-2020)
    • 11.16.4 Innate Immunotherapeutics Products Offered
    • 11.16.5 Innate Immunotherapeutics Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)

  • 12.1 Multiple Sclerosis (MS) Drugs Market Estimates and Projections by Region
    • 12.1.1 Global Multiple Sclerosis (MS) Drugs Sales Forecast by Regions 2021-2026
    • 12.1.2 Global Multiple Sclerosis (MS) Drugs Revenue Forecast by Regions 2021-2026
  • 12.2 North America Multiple Sclerosis (MS) Drugs Market Size Forecast (2021-2026)
    • 12.2.1 North America: Multiple Sclerosis (MS) Drugs Sales Forecast (2021-2026)
    • 12.2.2 North America: Multiple Sclerosis (MS) Drugs Revenue Forecast (2021-2026)
    • 12.2.3 North America: Multiple Sclerosis (MS) Drugs Market Size Forecast by Country (2021-2026)
  • 12.3 Europe Multiple Sclerosis (MS) Drugs Market Size Forecast (2021-2026)
    • 12.3.1 Europe: Multiple Sclerosis (MS) Drugs Sales Forecast (2021-2026)
    • 12.3.2 Europe: Multiple Sclerosis (MS) Drugs Revenue Forecast (2021-2026)
    • 12.3.3 Europe: Multiple Sclerosis (MS) Drugs Market Size Forecast by Country (2021-2026)
  • 12.4 Asia Pacific Multiple Sclerosis (MS) Drugs Market Size Forecast (2021-2026)
    • 12.4.1 Asia Pacific: Multiple Sclerosis (MS) Drugs Sales Forecast (2021-2026)
    • 12.4.2 Asia Pacific: Multiple Sclerosis (MS) Drugs Revenue Forecast (2021-2026)
    • 12.4.3 Asia Pacific: Multiple Sclerosis (MS) Drugs Market Size Forecast by Region (2021-2026)
  • 12.5 Latin America Multiple Sclerosis (MS) Drugs Market Size Forecast (2021-2026)
    • 12.5.1 Latin America: Multiple Sclerosis (MS) Drugs Sales Forecast (2021-2026)
    • 12.5.2 Latin America: Multiple Sclerosis (MS) Drugs Revenue Forecast (2021-2026)
    • 12.5.3 Latin America: Multiple Sclerosis (MS) Drugs Market Size Forecast by Country (2021-2026)
  • 12.6 Middle East and Africa Multiple Sclerosis (MS) Drugs Market Size Forecast (2021-2026)
    • 12.6.1 Middle East and Africa: Multiple Sclerosis (MS) Drugs Sales Forecast (2021-2026)
    • 12.6.2 Middle East and Africa: Multiple Sclerosis (MS) Drugs Revenue Forecast (2021-2026)
    • 12.6.3 Middle East and Africa: Multiple Sclerosis (MS) Drugs Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

  • 13.1 Market Opportunities and Drivers
  • 13.2 Market Challenges
  • 13.3 Market Risks/Restraints
  • 13.4 Porter's Five Forces Analysis
  • 13.5 Primary Interviews with Key Multiple Sclerosis (MS) Drugs Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

  • 14.1 Value Chain Analysis
  • 14.2 Multiple Sclerosis (MS) Drugs Customers
  • 14.3 Sales Channels Analysis
    • 14.3.1 Sales Channels
    • 14.3.2 Distributors

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Research Methodology
      • 16.1.1 Methodology/Research Approach
      • 16.1.2 Data Source
    • 16.2 Author Details

    Summary:
    Get latest Market Research Reports on Multiple Sclerosis (MS) Drugs . Industry analysis & Market Report on Multiple Sclerosis (MS) Drugs is a syndicated market report, published as Global Multiple Sclerosis (MS) Drugs Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Multiple Sclerosis (MS) Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,900.00
    		$5,850.00
    		$7,800.00
    		3,014.70
    		4,522.05
    		6,029.40
    		3,630.90
    		5,446.35
    		7,261.80
    		595,491.00
    		893,236.50
    		1,190,982.00
    		329,160.00
    		493,740.00
    		658,320.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo